This modular platform enabled efficient degradation of nuclear (bromodomain-containing protein 4, BRD4), cytosolic (nicotinamide phosphoribosyl transferase, NAMPT), and membrane (discoidin domain receptor 1, DDR1) targets, suppressed oncogenic signaling, and achieved nearly complete tumor growth inhibition in vivo with negligible toxicity. The gene discussed is NAMPT; the disease is neoplasm.